Abstract
Hereditary spinocerebellar ataxia (SCA) is a devastating, incurable disease. Stem-cell-based therapies represent new promise for clinical research in neurology. The objectives of this study were to assess the feasibility, efficacy, and potential toxicity of human umbilical cord mesenchymal stem cells (UCMSCs) therapy in patients with SCA. Sixteen genomically diagnosed SCA patients were enrolled and received intravenous and intrathecal infusion of UCMSCs. Clinical, laboratory, and radiographic evaluations were conducted to assess the safety of UCMSC therapy. Efficacy was evaluated by the Berg Balance Scale (BBS) and International Cooperative Ataxia Rating Scale (ICARS) scores. Among the 16 cases, there were no serious transplant-related adverse events happened in 12 months follow-up. The majority of patients showed improved BBS and ICARS scores continuing for at least 6 months which indicated UCMSC therapy could alleviate SCA symptoms. This study suggested that UCMSC transplantation was safe and might delay the progression of SCA. This may represent a new therapeutic strategy for SCA and other genetic neurological diseases.
Keywords: Berg Balance Scale, Efficacy, International Cooperative Ataxia Rating Scale, Safety, Spinocerebellar Ataxia, Umbilical Cord Mesenchymal Stem Cell
Current Neurovascular Research
Title:Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy in Hereditary Spinocerebellar Ataxia
Volume: 10 Issue: 1
Author(s): Jia-Li Jin, Zhuo Liu, Zhen-Juan Lu, De-Ning Guan, Chong Wang, Zhi-Bin Chen, Jun Zhang, Wei-Yun Zhang, Jia-Yong Wu and Yun Xu
Affiliation:
Keywords: Berg Balance Scale, Efficacy, International Cooperative Ataxia Rating Scale, Safety, Spinocerebellar Ataxia, Umbilical Cord Mesenchymal Stem Cell
Abstract: Hereditary spinocerebellar ataxia (SCA) is a devastating, incurable disease. Stem-cell-based therapies represent new promise for clinical research in neurology. The objectives of this study were to assess the feasibility, efficacy, and potential toxicity of human umbilical cord mesenchymal stem cells (UCMSCs) therapy in patients with SCA. Sixteen genomically diagnosed SCA patients were enrolled and received intravenous and intrathecal infusion of UCMSCs. Clinical, laboratory, and radiographic evaluations were conducted to assess the safety of UCMSC therapy. Efficacy was evaluated by the Berg Balance Scale (BBS) and International Cooperative Ataxia Rating Scale (ICARS) scores. Among the 16 cases, there were no serious transplant-related adverse events happened in 12 months follow-up. The majority of patients showed improved BBS and ICARS scores continuing for at least 6 months which indicated UCMSC therapy could alleviate SCA symptoms. This study suggested that UCMSC transplantation was safe and might delay the progression of SCA. This may represent a new therapeutic strategy for SCA and other genetic neurological diseases.
Export Options
About this article
Cite this article as:
Jin Jia-Li, Liu Zhuo, Lu Zhen-Juan, Guan De-Ning, Wang Chong, Chen Zhi-Bin, Zhang Jun, Zhang Wei-Yun, Wu Jia-Yong and Xu Yun, Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy in Hereditary Spinocerebellar Ataxia, Current Neurovascular Research 2013; 10 (1) . https://dx.doi.org/10.2174/1567202611310010003
DOI https://dx.doi.org/10.2174/1567202611310010003 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development and Potential Utility of Dual and Triple NK Receptor Antagonists
Current Topics in Medicinal Chemistry Changes of Gene Expression in the Developing Brain by Acute Ethanol Exposure
Current Psychopharmacology Nanotheranostics in Evidence Based Personalized Medicine
Current Drug Targets Can We Selectively Reduce Appetite for Energy-Dense Foods? An Overview of Pharmacological Strategies for Modification of Food Preference Behavior
Current Neuropharmacology The Inhibition of Histone Deacetylases Reduces the Reinstatement of Cocaine-Seeking Behavior in Rats
Current Neuropharmacology Purinergic Signaling and Energy Homeostasis in Psychiatric Disorders
Current Molecular Medicine Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) The Start of a New Era for Stroke Treatment: Mechanical Thrombectomy Devices
Current Neurovascular Research PTML Modeling for Alzheimer’s Disease: Design and Prediction of Virtual Multi-Target Inhibitors of GSK3B, HDAC1, and HDAC6
Current Topics in Medicinal Chemistry HIV-1 Infection in Subjects Older than 70: A Multicenter Cross-Sectional Assessment in Catalonia, Spain
Current HIV Research Balance Between S6K-S6 and 4E-BP1 Depends on ERK Activity in Developing Neurons
Current Signal Transduction Therapy Exercise and Cognitive-Behavioural Treatment in Fibromyalgia Syndrome
Current Pharmaceutical Design Editorial - Coping with Neuropathic Pain: Do We Need More Selective Analgesic Drugs?
Current Pharmaceutical Design Influence of Lifestyle Measures on Hypertriglyceridaemia
Current Drug Targets Editorial (Thematic Issue: Health Impact and Management of a Disrupted Circadian Rhythm and Sleep in Critical Illnesses)
Current Pharmaceutical Design HspB1 Dynamic Phospho-Oligomeric Structure Dependent Interactome as Cancer Therapeutic Target
Current Molecular Medicine Potential Roles of Selenium and Selenoproteins in the Prevention of Alzheimer's Disease
Current Topics in Medicinal Chemistry Activity of γ -Secretase on Substrates Other than APP
Current Topics in Medicinal Chemistry Neurotoxic and Neuroactive Compounds from Cnidaria: Five Decades of Research….and More
Central Nervous System Agents in Medicinal Chemistry